Form 4: Pliant Therapeutics Director Receives Stock Option Grant

Director Hoyoung Huh was granted 70,000 stock options in Pliant Therapeutics as part of standard equity compensation.

Summary

• Director Hoyoung Huh received a grant of 70,000 stock options for Pliant Therapeutics (PLRX) common stock.
• The options have an exercise price of $1.14 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 11, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Equity-based compensation aligns the interests of the director with those of the shareholders.

Negatives

• The issuance of new stock options results in potential future dilution for existing shareholders.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• Vesting is subject to the director's continued service to the issuer.

Future Outlook

The options vest in quarterly increments starting October 1, 2026, through the one-year anniversary of the grant or the next annual meeting, indicating a long-term retention incentive for the director.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain experienced board members, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The grant of 70,000 options is consistent with typical director compensation packages for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings or service anniversaries align with standard corporate governance practices in the U.S. life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of 25% of options on October 1, 2026.
• Vesting of subsequent tranches on January 1, 2027, and April 1, 2027.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Form 4, Insider Trading, Stock Options, Director Compensation